Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
59
CRON Quote, Financials, Valuation and Earnings
Last price:
$2.69
Seasonality move
:
-12.91%
Day range:
$2.65 - $2.72
52-week range:
$1.60 - $3.43
Dividend yield:
0%
P/E ratio:
28.91x
P/S ratio:
7.85x
P/B ratio:
0.96x
Volume:
1.3M
Avg. volume:
1.3M
1-year change:
37.76%
Market cap:
$1B
Revenue:
$117.6M
EPS (TTM):
$0.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRON
Cronos Group, Inc.
|
$39.5M | -$0.05 | 29.05% | -151.88% | $2.30 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 20.79% | 10.43% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$100K | -- | -42.53% | -- | $4.50 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.06 | -- | -9.31% | $10.30 |
|
TLRY
Tilray Brands, Inc.
|
$211.1M | -- | 8.44% | -100% | $11.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRON
Cronos Group, Inc.
|
$2.70 | $2.30 | $1B | 28.91x | $0.00 | 0% | 7.85x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$14.40 | $16.67 | $1.9B | 25.66x | $0.00 | 0% | 7.64x |
|
EDSA
Edesa Biotech, Inc.
|
$0.90 | $11.00 | $7.5M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.66 | $4.50 | $16.4M | -- | $0.00 | 0% | 24.25x |
|
ONCY
Oncolytics Biotech, Inc.
|
$1.00 | $10.30 | $107.6M | -- | $0.00 | 0% | -- |
|
TLRY
Tilray Brands, Inc.
|
$7.89 | $11.83 | $915.2M | -- | $0.00 | 0% | 0.95x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRON
Cronos Group, Inc.
|
0.16% | 0.837 | 0.16% | 20.73x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | 0.004 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -1.338 | -- | 16.51x |
|
LEXX
Lexaria Bioscience Corp.
|
2.03% | -0.383 | 0.43% | 3.04x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.996 | 0.41% | 1.61x |
|
TLRY
Tilray Brands, Inc.
|
16.83% | 3.038 | 35.13% | 1.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRON
Cronos Group, Inc.
|
$18M | -$5M | 3.69% | 3.69% | -13.83% | $8.9M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.5K | -$2.3M | -66.98% | -66.98% | -- | -$2.1M |
|
LEXX
Lexaria Bioscience Corp.
|
-$24.2K | -$1.6M | -186.06% | -189.86% | -2155.4% | -$989.2K |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
TLRY
Tilray Brands, Inc.
|
$53.1M | -$20M | -84.8% | -98.18% | -9.2% | -$18M |
Cronos Group, Inc. vs. Competitors
-
Which has Higher Returns CRON or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of 42.95%. Cronos Group, Inc.'s return on equity of 3.69% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital CRONCronos Group, Inc.49.47% $0.07 $1.1B AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About CRON or AUPH?
Cronos Group, Inc. has a consensus price target of $2.30, signalling downside risk potential of -14.84%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 15.74%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than Cronos Group, Inc., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than Cronos Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRONCronos Group, Inc.2 1 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is CRON or AUPH More Risky?
Cronos Group, Inc. has a beta of 0.804, which suggesting that the stock is 19.636% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.504, suggesting its more volatile than the S&P 500 by 50.415%.
-
Which is a Better Dividend Stock CRON or AUPH?
Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRON or AUPH?
Cronos Group, Inc. quarterly revenues are $36.3M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Cronos Group, Inc.'s net income of $28.3M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 28.91x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 25.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.85x versus 7.64x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRONCronos Group, Inc.7.85x 28.91x $36.3M $28.3M AUPHAurinia Pharmaceuticals, Inc.7.64x 25.66x $73.5M $31.6M
-
Which has Higher Returns CRON or EDSA?
Edesa Biotech, Inc. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of --. Cronos Group, Inc.'s return on equity of 3.69% beat Edesa Biotech, Inc.'s return on equity of -66.98%.
Company Gross Margin Earnings Per Share Invested Capital CRONCronos Group, Inc.49.47% $0.07 $1.1B EDSAEdesa Biotech, Inc.-- -$0.28 $14M -
What do Analysts Say About CRON or EDSA?
Cronos Group, Inc. has a consensus price target of $2.30, signalling downside risk potential of -14.84%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 1118.3%. Given that Edesa Biotech, Inc. has higher upside potential than Cronos Group, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Cronos Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRONCronos Group, Inc.2 1 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is CRON or EDSA More Risky?
Cronos Group, Inc. has a beta of 0.804, which suggesting that the stock is 19.636% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.208, suggesting its less volatile than the S&P 500 by 79.169%.
-
Which is a Better Dividend Stock CRON or EDSA?
Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRON or EDSA?
Cronos Group, Inc. quarterly revenues are $36.3M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Cronos Group, Inc.'s net income of $28.3M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 28.91x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.85x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRONCronos Group, Inc.7.85x 28.91x $36.3M $28.3M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns CRON or LEXX?
Lexaria Bioscience Corp. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of -2178.51%. Cronos Group, Inc.'s return on equity of 3.69% beat Lexaria Bioscience Corp.'s return on equity of -189.86%.
Company Gross Margin Earnings Per Share Invested Capital CRONCronos Group, Inc.49.47% $0.07 $1.1B LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M -
What do Analysts Say About CRON or LEXX?
Cronos Group, Inc. has a consensus price target of $2.30, signalling downside risk potential of -14.84%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 582.03%. Given that Lexaria Bioscience Corp. has higher upside potential than Cronos Group, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Cronos Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRONCronos Group, Inc.2 1 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is CRON or LEXX More Risky?
Cronos Group, Inc. has a beta of 0.804, which suggesting that the stock is 19.636% less volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.562, suggesting its less volatile than the S&P 500 by 43.753%.
-
Which is a Better Dividend Stock CRON or LEXX?
Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRON or LEXX?
Cronos Group, Inc. quarterly revenues are $36.3M, which are larger than Lexaria Bioscience Corp. quarterly revenues of --. Cronos Group, Inc.'s net income of $28.3M is higher than Lexaria Bioscience Corp.'s net income of -$1.6M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 28.91x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.85x versus 24.25x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRONCronos Group, Inc.7.85x 28.91x $36.3M $28.3M LEXXLexaria Bioscience Corp.24.25x -- -- -$1.6M
-
Which has Higher Returns CRON or ONCY?
Oncolytics Biotech, Inc. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of --. Cronos Group, Inc.'s return on equity of 3.69% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital CRONCronos Group, Inc.49.47% $0.07 $1.1B ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About CRON or ONCY?
Cronos Group, Inc. has a consensus price target of $2.30, signalling downside risk potential of -14.84%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $10.30 which suggests that it could grow by 456.5%. Given that Oncolytics Biotech, Inc. has higher upside potential than Cronos Group, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Cronos Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRONCronos Group, Inc.2 1 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is CRON or ONCY More Risky?
Cronos Group, Inc. has a beta of 0.804, which suggesting that the stock is 19.636% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.202%.
-
Which is a Better Dividend Stock CRON or ONCY?
Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRON or ONCY?
Cronos Group, Inc. quarterly revenues are $36.3M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Cronos Group, Inc.'s net income of $28.3M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 28.91x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.85x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRONCronos Group, Inc.7.85x 28.91x $36.3M $28.3M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns CRON or TLRY?
Tilray Brands, Inc. has a net margin of 77.94% compared to Cronos Group, Inc.'s net margin of -20%. Cronos Group, Inc.'s return on equity of 3.69% beat Tilray Brands, Inc.'s return on equity of -98.18%.
Company Gross Margin Earnings Per Share Invested Capital CRONCronos Group, Inc.49.47% $0.07 $1.1B TLRYTilray Brands, Inc.24.43% -$0.41 $1.9B -
What do Analysts Say About CRON or TLRY?
Cronos Group, Inc. has a consensus price target of $2.30, signalling downside risk potential of -14.84%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $11.83 which suggests that it could grow by 49.87%. Given that Tilray Brands, Inc. has higher upside potential than Cronos Group, Inc., analysts believe Tilray Brands, Inc. is more attractive than Cronos Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRONCronos Group, Inc.2 1 0 TLRYTilray Brands, Inc.2 7 0 -
Is CRON or TLRY More Risky?
Cronos Group, Inc. has a beta of 0.804, which suggesting that the stock is 19.636% less volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 2.022, suggesting its more volatile than the S&P 500 by 102.181%.
-
Which is a Better Dividend Stock CRON or TLRY?
Cronos Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group, Inc. pays -- of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRON or TLRY?
Cronos Group, Inc. quarterly revenues are $36.3M, which are smaller than Tilray Brands, Inc. quarterly revenues of $217.5M. Cronos Group, Inc.'s net income of $28.3M is higher than Tilray Brands, Inc.'s net income of -$43.5M. Notably, Cronos Group, Inc.'s price-to-earnings ratio is 28.91x while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group, Inc. is 7.85x versus 0.95x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRONCronos Group, Inc.7.85x 28.91x $36.3M $28.3M TLRYTilray Brands, Inc.0.95x -- $217.5M -$43.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
